Form D · Hedge Fund
Ataraxa LP
New York, NY · CIK 0002053057
Offering snapshot reported Jan 30, 2025 · SEC filing
- Reported sold
- $1.04M Indefinite offering
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Jan 15, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 30, 2025 | Initial | $1,035,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Pooled investment fund
- Exemptions
- 06b, 3C, 3C.1
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-536778
The reported amount sold and number of investors represent total contributions by all investors in the issue since inception. The current assets under management and current number of investors may be significantly different.
Source: Form D, filed Jan 30, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| N/A Ataraxa Gp Llc | Executive |
| N/A Avenir Management Company, Llc | Executive |
| James Reynolds Iv | Promoter |
| Andrew Sugrue | Promoter |
Issuer details
Industry: Pooled Investment Fund (See others in industry)
Address:
817 Broadway 12 Th Floor
New York, NY, 10003
New York, NY, 10003